5
Jan
2018

Spark Sets $850K Bar, Microsoft’s Bet on AI for Immune Mapping, & Startup Financings Galore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Novartis Doubles Down on Radiopharma, Activation Lethality and FTC Nastygrams
Day One’s Home Run, Big Pharma’s Missed Opportunity, and Tessier-Lavigne Rides Again
WuXi Feels Heat, Cerevel Hits Parkinson’s Goal & More GLP-1 Good News
Vertex Antes for Alpine, Regeneron Faces DOJ Scrutiny, & the Illumina Shakeup